Blinatumomab (Blincyto®) Overview

•  Availability in India

Blinatumomab is a cancer medicine that is sold under the brand name Blincyto. It is used to treat a blood cancer called B-precursor acute lymphoblastic leukemia in patients of age one year and above. Its usage is accompanied by patients whose cancer has relapsed or has not improved with previous treatment. It can also be used in these patients as part of ‘consolidation therapy’ to improve the diminution of cancer. Blincyto is used in patients who have the protein CD19 on their cancer cells and are ‘Philadelphia-chromosome-negative’ (Ph-negative), which means that the patient’s cancer cells do not have an abnormal chromosome called the Philadelphia chromosome.

It is available in India for use and can be supplied by an approved generic medication supplier.

We are the most reliable suppliers to buy Blincyto 38.5 mcg at economical prices.

•  Dosage Strength and Administration

It can easily be purchased as Blincyto's price in India is pocket friendly and can only be obtained with a prescription, and treatment should be started by a medical specialist who has experience in the treatment of patients with cancers of the blood. It is available in injections as 35 mcg lyophilized powder in a single dose via injection is available for Administration. Before the treatment, body weight is monitored, and the dose is calculated on the basis of weight. It is given by dripping the vein, and the infusion is done intravenously only by a pump device.

For reconstitution, add 3 mL of preservative-free Sterile Water for Injection of USP directly into the walls of BLINCYTO, and the resulting final concentration is 12.5 mcg/mL. The prepared infusion is gently swirled, and excess foam is avoided. If there is any particulate matter or any sort of discoloration is observed, the batch of prepared BLINCYTO must be discarded and should not be used. After preparation, the prepared BLINCYTO-infused bag must be continuously induced over a period of 24 or 48 hours.

For treatment of relapsed or refractory B-precursor ALL, the dose depends on the patient’s weight. Blincyto is infused continuously for four weeks as part of the treatment cycle. Each cycle is separated by an interval after a two-week treatment. Patients are treated with an additional three cycles of BLINCYTO and have no signs of cancer after two cycles if the benefits outweigh the risks for the patient.

It can be obtained from various suppliers, and you can also buy BLINCYTO online from

• Method Of Action

In B-precursor ALL, certain cells that give rise to a type of white blood cell called B cells multiply too quickly, and they eventually replace normal blood cells with abnormal cells. The active substance in Blincyto is blinatumomab which is an antibody that has been designed to attach to a CD19( a protein) found on B cells, including ALL cells. It also attaches to a protein (CD3) in T cells. T cells are another type of white blood cell.

Hence, Blincyto acts as a ‘bridge’, bringing T cells and B cells together. It causes the T cells to release substances that kill the cancerous B cells eventually.

People who have blood cancer of this kind can get this medicine against a prescription from any of the suppliers at economical prices, as the cost of BLINCYTO in India, is budget-friendly.

• Adverse Reactions and Side Effects

BLINCYTO injection can cause some side effects. Most common adverse reactions associated with BLINCYTO are infections, fever, infusion-related reactions, headache, febrile neutropenia, constipation, nausea, diarrhea, vomiting, anemia (low red blood cell counts), edema (swelling because of fluid retention), neutropenia (low levels of neutrophils, a type of white blood cell), leucopenia (low levels of white blood cell), thrombocytopenia (low platelet count), blood tests showing changes in liver function, tremor (shaking), back pain, chills, low blood pressure, low levels of immunoglobulins (antibodies), cytokine release syndrome (a life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure), rapid heartbeat, insomnia (difficulty sleeping), pain in the arms and legs, abdominal (belly) pain, cough and rash.

Most serious reactions associated with BLINCYTO include neutropenia with or without fever, infections, cytokine release syndrome, and tumor lysis syndrome.

Apart from all these side effects, it is very efficient if used properly under the supervision of an expert doctor.

Moreover, BLINCYTO injection price in India is economical, and it can be purchased at reasonable rates. For more detail on the adverse effects of the drug, Call/WhatsApp (+91) 8130290915 or Email us on info@ikrispharmanetwork.com

•  Drug Interactions

There are no formal drug interaction studies that have been conducted with BLINCYTO. Starting the treatment of BLINCYTO causes the transient release of cytokines which may suppress CYP450 enzymes. During the first 9 days of the first cycle and the first 2 days of the second cycle in patients who are receiving concomitant CYP450 substrates, there are the highest drug-drug interaction risk, particularly those with a narrow therapeutic index. In these patients, monitor for toxicity (e.g., warfarin) or drug concentrations (e.g., cyclosporine). Adjust the dose of the concomitant drug as needed.

• USE IN SPECIFIC POPULATION

● Pregnancy- BLINCYTO may cause fetal harm, including B-cell lymphocytopenia, when

administered to a pregnant woman according to their method of action. There is no data on the

use of BLINCYTO in pregnant women, but it is advised to pregnant women not to use it because

it may cross the placental barrier shown in animal studies and may cause potential risks to a fetus.

The background rate of major birth defects and miscarriage is unknown for the indicated

population. It is easily available as you can buy BLINCYTO online, so all the side effects and

use must be understood properly and used in an efficient and safer way.

● Lactation- There is no information regarding the presence of blinatumomab in human milk or the effects on the breastfed infant, or the effects on the production of milk. Because of the fact many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from BLINCYTO, including B-cell lymphocytopenia, it is advised to patients not to breastfeed during and for at least 48 hours after treatment with BLINCYTO.

Full restrictions can be seen on the package leaflet. To know more about BLINCYTO price in India you can email us at info@indianpharmanetwork.in

• STORAGE

Each BLINCYTO package contains one BLINCYTO 35 mcg single-dose vial containing a sterile,

preservative-free, white to off-white lyophilized powder and one intravenous Solution stabilizer of 10 mL single-dose glass vial containing a sterile, preservative-free, colorless to a slightly yellow, clear solution. It is clearly mentioned not to use the IV Solution Stabilizer to reconstitute BLINCYTO. BLINCYTO and IV Solution Stabilizer vials in the original package are stored and refrigerated at 2°C to 8°C (36°F to 46°F) and protected from light until the time of use. Do not freeze. Store and transport the prepared intravenous bag containing BLINCYTO solution for infusion at 2°C to 8°C (36°F to 46°F) conditions. Ship in packaging that has been validated to maintain the temperature of the contents at 2°C to 8°C (36°F to 46°F).

Indian pharma network has expertise in cold chains, so the drug is exported in a safer manner and delivered more efficiently. We serve our patients the best thing possible, and to know more about BLINCYTO cost you can visit us at Contact us: Ikris Pharma Network | Toll-Free:- 1800 889 1064

• DESCRIPTION

It is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 and CD3. BLINCYTO is

produced in Chinese hamster ovary cells. It contains 504 amino acids, which have a molecular weight of approximately 54 kilodaltons. Each BLINCYTO package contains 1 vial BLINCYTO and 1 vial IV Solution Stabilizer. BLINCYTO is supplied in a single-dose vial as a sterile, preservative-free, white to off-white lyophilized powder for intravenous Administration. Each single-dose vial of BLINCYTO contains 35 mcg drug, and the Blincyto injection price is pocket efficient. It also contains citric acid monohydrate (3.35 mg), lysine hydrochloride (23.23 mg), polysorbate 80 (0.64 mg), trehalose dihydrate (95.5 mg), and sodium hydroxide to adjust pH to 7.0. After reconstitution with 3 mL of preservative-free Sterile Water for injection, USP, the resulting concentration is 12.5 mcg/mL blinatumomab. IV Solution Stabilizer is supplied in a single-dose vial which is sterile, preservative-free, colorless to a slightly yellow, clear solution.

Each single-dose vial of IV Solution Stabilizer contains citric acid monohydrate (52.5 mg), lysine hydrochloride (2283.8 mg), polysorbate 80 (10 mg), sodium hydroxide to adjust pH to 7.0, and Water for injection. To know more about BLINCYTO price, you can Call/WhatsApp us at (+91 9310090915)

MITOTANE Dosage and Mechanism

 Mitotane is a potent cancer medicine which is sold under the brand name LYSODREN. It is used in the treatment of patients with advanced adrenal cortical carcinoma, which is basically a kind of cancer of the outer layer of the adrenal gland. Mitotane is a cytotoxic agent which is used when cancer is inoperable, either functional or non-functional and relapsed. 

Patients with adrenal cortical carcinoma are low; hence it is considered 'rare', and LYSODREN is taken as an orphan medicine for this rare disease. It is available in India, and lysodren's price is economical and can be easily purchased by any authorized supplier against a valid prescription.

How to take Mitotane?

It is available as 500mg tablets, and the initial dose is 2 g to 6 g orally daily, in three or four divided doses, taken with meals containing fatty foods. Increase the dose incrementally to achieve a blood concentration of 14 to 20 mg/l, or as tolerated, and the levels of the active substance in the blood should be monitored frequently. 

Levels above 20 mg/L may cause severe side effects without increasing the medicine's effectiveness. The medicine should be taken till the time it is effective and must be withdrawn if there are any side effects. Indian Pharma Network is among the reliable platforms which facilitate patients' connection with genuine pharmaceutical suppliers, wholesalers, and dealers. To know more details about the cost of MITOTANE in India, contact us at https://indianpharmanetwork.in/contact-us/ 

There is limited information on the use of Lysodren in children, but a daily starting dose of 1.5 to 3.5 g per square meter of body surface area is recommended.

How does MITOTANE work?

Mitotane is a white granular solid composed of clear, colorless crystals. It is tasteless and has a slightly pleasant aromatic odour. Steroid hormones are produced by the cortex of the adrenal gland. When this area develops cancer, levels of these hormones can increase, which causes the symptoms of the disease. The active substance in Lysodren, Mitotane, is thought to work by inhibiting cells in the adrenal gland from working properly and by damaging their mitochondria, there is a reduction in some steroid hormones. It may also alter the breakdown of these hormones. Together, these effects reduce the levels of the hormones in the body, improving the symptoms of the disease. But the exact mechanism of this cytotoxic agent is still unknown. 

Patients taking recommended doses of Mitotane can get benefits fighting against this cancer, and Mitotane 500 mg tablets at economical prices can be obtained through Indian Pharma Network.

For more details about Mitotane, call us at our toll-free number, 18008891064; we will be happy to help you.

Trodelvy for unresectable locally advanced

 "Unresectable locally advanced" is a medical term that describes a situation where a cancerous tumor has grown to a point where it cannot be removed surgically. This can happen because the tumor has grown into or around vital organs, blood vessels, or nerves, making it too risky to attempt surgery.

In these cases, doctors may recommend other treatment options, such as radiation therapy, chemotherapy, targeted therapy, immunotherapy, or a combination of these. The goal of treatment is to shrink the tumor and slow down its growth, alleviate symptoms, improve quality of life, and potentially increase survival.

It is important for patients with unresectable locally advanced cancer to work closely with their healthcare team to determine the best treatment plan for their specific situation. They may also consider seeking a second opinion to ensure they are receiving the most appropriate care.

Trodelvy (sacituzumab govitecan-hziy) is a medication used to treat certain types of cancer. Specifically, it is used to treat adults with metastatic triple-negative breast cancer (TNBC) who have received at least two prior treatments for their disease. It is also used to treat adults with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.

Trodelvy is a type of medication called an antibody-drug conjugate. It works by targeting a protein called Trop-2, which is present on the surface of certain cancer cells. The medication is made up of two parts: an antibody that targets the Trop-2 protein and a chemotherapy drug that is attached to the antibody. When the medication attaches to the cancer cell, it releases the chemotherapy drug, which enters the cancer cell and destroys it.

The medication is given as an intravenous (IV) infusion, meaning it is administered directly into a vein over a period of time. The dosage and frequency of treatment will depend on the individual patient's condition and response to treatment.

Like all medications, Trodelvy can cause side effects. Common side effects may include fatigue, nausea, diarrhea, anemia, hair loss, and decreased appetite. More serious side effects may include infections, bleeding, and infusion-related reactions. It is important for patients receiving this treatment to discuss potential side effects with their healthcare provider and report any concerning symptoms promptly.

Triple-negative breast cancer Treatment

 Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This subtype of breast cancer is more aggressive and difficult to treat than other types of breast cancer, as it does not respond to hormonal therapies or targeted therapies that are effective against ER-positive, PR-positive, or HER2-positive breast cancers.

The treatment of TNBC depends on the stage of cancer and other individual factors such as age, overall health, and personal preferences. The main treatment options for TNBC include:

• Surgery: Surgery is usually the first treatment for TNBC. The aim of surgery is to remove as much cancer as possible. This may involve a lumpectomy (removal of the tumor and a surrounding margin of healthy tissue) or a mastectomy (removal of the entire breast).

• Chemotherapy: Chemotherapy is often used after surgery to reduce the risk of cancer coming back. It may also be used as the primary treatment for TNBC that has spread beyond the breast. Chemotherapy drugs are given intravenously or orally and are designed to kill cancer cells.

• Radiation therapy: Radiation therapy uses high-energy beams to destroy cancer cells. It is often given after surgery to kill any remaining breast or lymph nodes cancer cells. It may also be used to relieve symptoms of advanced TNBC.

• Immunotherapy: Immunotherapy is a targeted therapy that stimulates the immune system to attack cancer cells. Pembrolizumab and atezolizumab are two immunotherapy drugs that have been approved for use in combination with chemotherapy for the treatment of advanced TNBC.

• Clinical trials: There are ongoing clinical trials investigating new treatments for TNBC, including targeted therapies and immunotherapies.

It is essential to work closely with a team of healthcare professionals to determine the best treatment plan for TNBC.

Blincyto Dosage Guidelines

 Blincyto (blinatumomab) is a prescription medication used to treat a specific type of blood cancer called B-cell precursor acute lymphoblastic leukemia (ALL). The dosage of Blincyto may vary based on the patient's body weight and the stage of the disease.

The recommended starting dose of Blincyto is 9 micrograms (mcg) per day, which is delivered through a continuous intravenous infusion (IV) for 28 days. After the first 28 days, the dosage is increased to 28 mcg per day for up to 3 additional cycles of 28 days each.

The dosage of Blincyto may need to be adjusted based on the patient's response to treatment and any side effects they experience. In some cases, the treatment may need to be interrupted or discontinued if severe side effects occur.

It is important to follow the dosing instructions provided by the prescribing healthcare provider and to contact them if you have any questions or concerns about your treatment with Blincyto.

Read -  Blincyto 38.5 mcg for acute lymphoblastic leukemia

Blincyto 38.5 mcg for acute lymphoblastic leukemia

 Blincyto (blinatumomab) is a medication used to treat a specific type of blood cancer called Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

The dose of  Blincyto is based on the patient's weight and is given as a continuous intravenous infusion. The recommended starting dose for adults is 9 mcg/day, which is gradually increased over several days to a target dose of 28 mcg/day. The maximum dose is 42 mcg/day.

However, you mentioned 38.5 mcg," which is not a standard dosage for Blincyto. It's possible that you made a mistake in your question or that you have been prescribed a different dosage based on your individual circumstances.

In any case, it's important to follow your healthcare provider's instructions regarding the dose and administration of Blincyto or any other medication.

BLINCYTO TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA

Blinatumomab (brand name Blincyto) is a medication used to treat a specific type of acute lymphoblastic leukemia (ALL) called Philadelphia chromosome-negative B-cell precursor ALL. Blinatumomab is a type of immunotherapy called a bispecific T-cell engager (BiTE) that works by connecting T-cells to cancer cells, which can help the immune system identify and destroy cancer cells.

Blinatumomab is given as an intravenous infusion over a period of four weeks, followed by a two-week break, and then another four-week infusion cycle. Treatment typically lasts for a total of six cycles. The medication is given in a hospital or infusion center, and patients are closely monitored for potential side effects.

Common side effects of Blinatumomab include fever, fatigue, headache, nausea, vomiting, diarrhea, and decreased appetite. More serious side effects can include infections, allergic reactions, neurological problems, and cytokine release syndrome, which is a potentially life-threatening immune response. Patients receiving Blinatumomab may also experience low levels of certain blood cells, which can increase the risk of bleeding or infections.

Blinatumomab can be a highly effective treatment for certain ALL types, but it is not suitable for everyone. It is important to discuss the potential risks and benefits of this medication with your doctor to determine if it is the right treatment for you.

ENHERTU: Adverse Drug Reactions

The most common side effects of Enhertu, including laboratory abnormalities, in patients with: metastatic breast cancer and HER2-mutant NSCLC were nausea, decreased white blood cell count, decreased hemoglobin, decreased neutrophil count, decreased lymphocyte count, fatigue, decreased platelet count, increased aspartate aminotransferase, vomiting, increased alanine aminotransferase, alopecia, increased blood alkaline phosphatase, constipation, musculoskeletal pain, decreased appetite, hypokalemia, diarrhea, and respiratory infection.

  Gastric cancer was decreased hemoglobin, decreased white blood cell count, decreased neutrophil count, decreased lymphocyte count, decreased platelet count, nausea, fatigue, increased blood alkaline phosphatase, decreased appetite, increased aspartate aminotransferase, increased alanine aminotransferase, diarrhea, hypokalemia, vomiting, constipation, increased blood bilirubin, pyrexia, and alopecia.

Apart from these side effects, the drug is all set to use safely by an expert medical specialist. One can buy ENHERTU 100 mg injection online through various generic medication suppliers like Indian Pharma Network. Visit Contact us: Ikris Pharma Network | Toll-Free:- 1800 889 1064

ENHERTU: Storage and Availability 

The drug Trastuzumab deruxtecan, sold under the brand name Enhertu and is Stored in vials in a refrigerator at 2ºC to 8ºC (36ºF to 46ºF) in the original carton to protect from light until the time of reconstitution. It is made available online to buy. One can easily buy ENHERTU 100mg injection online or by contacting dealers who are recognized generic and innovative medication suppliers.